ARIAD Pharmaceuticals have announced the initiation of a phase II clinical trial of mTOR inhibitor deforolimus in patients with advanced endometrial cancer.
Filed under: kinase | Tagged: AP-23573, AP23573, Ariad, deforolimus, kinase, Merck, MK-8669, MK8669, mTOR, Phase II | Comments Off
